FPI-2119 Takes Center Stage at ESCMID Global 2026

Antibiotic resistance is one of the most urgent public health challenges of our time — and the research community is fighting back. During April 2026, Fedora Pharmaceuticals presented a comprehensive body of preclinical data on its lead candidate, FPI-2119, at ESCMID Global 2026 in Munich, Germany (April 17–21). With eight poster presentations, the breadth of evidence reflects the potential of FPI-2119 to become a transformative new tool against Gram-negative bacterial infections.

What is ESCMID Global 2026?

ESCMID Global is the annual congress of the European Society of Clinical Microbiology and Infectious Diseases — the world’s largest infectious diseases conference, bringing together over 16,000 clinicians, researchers, and policymakers. For Fedora, presenting there signals to the infectious disease community that FPI-2119 is a serious candidate worthy of scientific and clinical attention.

Why FPI-2119 matters

Many of the pathogens targeted by FPI-2119 — including Pseudomonas aeruginosa, Klebsiella pneumoniae, Acinetobacter baumannii, and drug-resistant Neisseria gonorrhoeae — appear on the World Health Organization’s Bacterial Priority Pathogens List. FPI-2119 is a first-in-kind derivative of the lactivicin class: a non-β-lactam antibiotic that lacks the classical ring structure that makes β-lactams vulnerable to β-lactamase enzymes.

Research into new antibacterial agents is scarce, yet pathogens continue to evolve new resistance mechanisms. Every year there are fewer reliably effective antibacterial agents, which puts hospital patients and the greater community at serious risk of succumbing to infections that were previously treatable.Karen Bush, Ph.D., Indiana University & Fedora Scientific Advisory Board

The eight ESCMID posters: key findings

• Pseudomonas aeruginosa (Poster 2568). Concentration-dependent bactericidal activity with a low frequency of resistance.
• β-lactamase-producing E. coli (Poster 2580). Potent activity maintained against strains carrying a broad range of β-lactamase genes.
• Enteric & respiratory pathogens (Poster 2581). Activity against resistant Campylobacter, Salmonella, Shigella, Haemophilus influenzae, and Moraxella catarrhalis.
• Neisseria gonorrhoeae (Poster 2583). All strains susceptible, including six resistant to penicillin, tetracycline, and ciprofloxacin.
• Safety (Poster 2599). No measurable cardiotoxicity and a clean off-target profile.
• MDR Gram-negatives (Poster 2601). Comparable or lower concentrations than cefepime against MDR P. aeruginosa, E. coli, and K. pneumoniae.
• Complicated UTI model (Poster 2643). Dose-dependent reductions in bacterial burden in bladder and kidney.
• Pharmacokinetics (Poster 2801). Data support potential once- or twice-daily dosing in humans.

Together, these candidates offer innovative strategies to address the urgent need to treat resistant infections.Christopher Micetich, CEO & Founder, Fedora Pharmaceuticals